Compare EXPO & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPO | ADPT |
|---|---|---|
| Founded | 1967 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 1990 | 2019 |
| Metric | EXPO | ADPT |
|---|---|---|
| Price | $66.75 | $16.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $90.50 | $17.78 |
| AVG Volume (30 Days) | 463.6K | ★ 1.9M |
| Earning Date | 02-05-2026 | 02-05-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $536,760,000.00 | $276,976,000.00 |
| Revenue This Year | $12.18 | N/A |
| Revenue Next Year | $8.47 | $23.05 |
| P/E Ratio | $32.27 | ★ N/A |
| Revenue Growth | 3.52 | ★ 54.77 |
| 52 Week Low | $63.81 | $6.26 |
| 52 Week High | $91.41 | $20.76 |
| Indicator | EXPO | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 35.89 |
| Support Level | $69.00 | $14.85 |
| Resistance Level | $81.95 | $17.98 |
| Average True Range (ATR) | 3.74 | 1.10 |
| MACD | -0.69 | -0.35 |
| Stochastic Oscillator | 6.97 | 14.24 |
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).